Cargando…
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease associated with more than 2468 human infections and over 851 deaths in 27 countries since 2012. There are no approved treatments for MERS-CoV infection although a combination of lopinavir,...
Autores principales: | Sheahan, Timothy P., Sims, Amy C., Leist, Sarah R., Schäfer, Alexandra, Won, John, Brown, Ariane J., Montgomery, Stephanie A., Hogg, Alison, Babusis, Darius, Clarke, Michael O., Spahn, Jamie E., Bauer, Laura, Sellers, Scott, Porter, Danielle, Feng, Joy Y., Cihlar, Tomas, Jordan, Robert, Denison, Mark R., Baric, Ralph S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954302/ https://www.ncbi.nlm.nih.gov/pubmed/31924756 http://dx.doi.org/10.1038/s41467-019-13940-6 |
Ejemplares similares
-
Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020) -
Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
por: Brown, Ariane J., et al.
Publicado: (2019) -
Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
por: Qomara, Windi Fresha, et al.
Publicado: (2021) -
Broad-spectrum Investigational Agent GS-5734 for the Treatment of Ebola, MERS Coronavirus and Other Pathogenic Viral Infections with High Outbreak Potential
por: Jordan, Robert, et al.
Publicado: (2017) -
Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir
por: Yin, Guosheng, et al.
Publicado: (2020)